Artesunate

Artesunate is indicated in the initial treatment of severe malaria.Artesunate for injection is an antimalarial drug used as the initial treatment of severe malaria in both adults and children. Typically, infusions of artesunate are continued for 2 to 7 days until the patient can tolerate oral antimalarial therapy. Artesunate therapy is associated with mild-to-moderate serum aminotransferase elevations during therapy but has not been linked instances of clinically apparent liver injury. It is grouped under the following drug class(es): Terpenes. Its therapeutic use is listed as anti-infectives, antimalarials and antiparasitics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Arsumax, Plasmotrin, Qinghaozhi and Saphnate. Its PubChem CID is 6917864.